Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Theriva Biologics Inc

TOVX ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$0.23

▼ -0.04%

Market Cap $10.33M · Vol 55.83K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$10.33M

Micro Cap

Div Yield

N/A

EPS Growth

+88.70%

YoY

RSI (14)

49.93

Momentum

Beta

1.25

vs Market

52W High

$0.86

73.93% below

52W Low

$0.16

37.95% above

Volume

55.83K

Avg 30.06K

P/B

0.49

Price-to-book

ROE

N/A

Return on equity

Free Float

98.37%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Theriva Biologics Inc (TOVX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does TOVX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.93%

-11.07%

-10.36%

-2.13%

YTD

+6.94%

-45.86%

-98.21%

-99.79%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-23,739,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-64.52% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.49
P/FCF	N/A
EPS Growth	+88.70%
Outstanding Shares	45.89M

Technical Indicators

50-Day SMA	$0.23
200-Day SMA	$0.24
RSI (14)	49.93
Beta	1.25
52-Week High	$0.86
52-Week Low	$0.16

Volume Today	55.83K
Avg Daily Volume (30D)	30.06K
Relative Volume	1.86x
Volatility (10D)	46.13
Volatility (30D)	45.28
Free Float	98.37%

Analyst Consensus

BUY

Current Price $0.23

Mean Target $2.50

52W Low$0.16 52W High$0.86

Current

Target

$0.16 $0.86

Current Analyst target

+1,011.11% upside potential · 2 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG001S77L07

ISINUS87164U5083

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 10, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. +1.14% ARGX.BR argenx SE -0.37% ARGX argenx SE -0.69% 2269.HK WuXi Biologics (Cayman) Inc. +1.56% INSM Insmed Incorporated -6.56%

Company Profile

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.